Medical management of secondary hyperparathyroidism in chronic renal failure

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 3, 2003, Pages

  Goodman, William G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcimimetic agents; Non calcium phosphate binding agents; Renal osteodystrophy; Vitamin D analogues

Indexed keywords

ALFACALCIDOL; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM CARBONATE; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM DERIVATIVE; CALCIUM ION; IRON DERIVATIVE; LANTHANUM; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

ALUMINUM OVERLOAD; ANEMIA; ARTERIOLOSCLEROSIS; ARTERY CALCIFICATION; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BRAIN DISEASE; CALCINOSIS; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; HEMODIALYSIS; HEMODYNAMICS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; METABOLIC BONE DISEASE; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN INTAKE; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; TREATMENT FAILURE; VALVULAR HEART DISEASE;

ADMINISTRATION, ORAL; CALCIUM; DIET; EPOXY COMPOUNDS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINES; POLYETHYLENES; VITAMIN D;

EID: 0038691694     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Goodman WG, Coburn JW, Slatopolsky E, Salusky IB. Renal osteodystrophy in adults and children. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Williams & Wilkins, Philadelphia: 1999: 347-363
2. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59: 1187-1201
3. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
5. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229-236
6. Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
7. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
8. Guèin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
9. Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2178-2183
10. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
11. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO (4), Ca x PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
12. Sanchez CP, Goodman WG, Salusky IB. Prevention of renal osteodystrophy in predialysis patients. Am J Med Sci 1999; 317: 398-404
13. Brown EM, Pollak M, Hebert SC. The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 1998; 49: 15-29
14. 2+. J Biol Chem 1986; 261: 2668-2674
15. Ramirez JA, Goodman WG, Gornbein J et al. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 1993; 76: 1489-1494
16. Brown EM. Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 1993; 2: 541-551
17. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3-9
18. Li YC, Amling M, Pirro AE et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391-4396
19. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993; 43: 436-442
20. NIH Consensus Statement. Optimal Calcium Intake 1994; 12: 1-31
21. Coburn JW, Kopple JD, Brickman AS. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973; 3: 264-272
22. Brickman AS, Coburn JW, Massry SG, Norman AW. 1,25-Dihydroxyvitamin D3 in normal man and patients with renal failure. Ann Intern Med 1974; 80: 161-168
23. Coburn JW, Norris KC, Nebeker HG. Osteomalacia and bone disease arising from aluminum. Semin Nephrol 1986; 6: 68-89
24. Goodman WG, Leite Duarte ME. Aluminum: effects on bone and role in the pathogenesis of renal osteodystrophy. Miner Electrolyte Metab 1991; 17: 221-232
25. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate is an effective phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161
26. Clarkson EM, McDonald SJ, de Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci 1966; 30: 425-438
27. Fournier A, Moriniere PH, Sebert JL et al. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia and hyperparathyroidism in uremia. Kidney Int 1986; 29: S115-S119
28. Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcaemia. Clin Nephrol 1987; 28: 222-226
29. Slatopolsky E, Weerts C, Norwood K et al. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989; 36: 897-903
30. Hutchison A, Freemont AJ, Boulton HF, Gokal R. Low calcium dialysis fluid and oral calcium carbonate in CAPD: a method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992; 7: 1219-1225
31. Zacharias JM, Fontaine B, Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int 1999; 19: 248-252
32. Mazhar AR, Johnson RJ, Gillen D et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324-332
33. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-738
34. Goodman WG. Historical perspective on the management of calcium and phosphorus metabolism in chronic renal failure: authors reply. Am J Kidney Dis 2001; 37: 197-201
35. Almaden Y, Canalejo A, Hernandez A et al. Direct effect of phosphorus on parathyroid hormone secretion from whole parathyroid glands in vitro. J Bone Miner Res 1996; 11: 970-976
36. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-2540
37. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28: 596-602
38. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273: 5253-5259
39. Llach F, Yudd M. The importance of hyperphosphataemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 1998; 13: 57-61
40. Mucsi I, Hercz G, Uldall R et al. Control of serum phosphorus without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53: 1399-1404
41. Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 1991; 17: 708-711
42. Bakir AA, Hryhorczuk DO, Berman E, Dunea G. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. Trans Am Soc Artif Intern Org 1986; 32: 171-176
43. Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71
44. Burke TJ, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 1640-1644
45. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
46. Hutchison AJ. Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy. Perit Dial Int 1999; 19 [Suppl. 2]: S408-S412
47. Delmez JA, Tindira C, Grooms P et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: a role for increased sensitivity to calcium. J Clin Invest 1989; 83: 1349-1355
48. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989; 36: 1093-1098
49. Felsenfeld AJ, Llach F. Parathyroid gland function in chronic renal failure. Kidney Int 1993; 43: 771-789
50. Goodman WG, Veldhuis JD, Belin TR et al. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 1998; 83: 2765-2772
51. Cardinal J, Brossard JH, Roy L et al. The set point of parathyroid hormone stimulation by calcium is normal in progressive renal failure. J Clin Endocrinol Metab 1998; 83: 3839-3844
52. Brown EM, Wilson RE, Eastmen RC, Pallotta J, Marynick S. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 1982; 54: 172-179
53. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56: 572-581
54. Okazaki T, Zajac JD, Igarashi T, Ogata E, Kronenberg HM. Negative regulatory elements in the human parathyroid hormone gene. J Biol Chem 1991; 266: 21903-21910
55. Okazaki T, Ando K, Igarashi T, Ogata E, Fujita T. Conserved mechanism of negative gene regulation by extracellular calcium: parathyroid hormone gene versus atrial natriuretic polypeptide gene. J Clin Invest 1992; 89: 1268-1273
56. Coburn JW, Salusky IB, Norris KC, Goodman WG. Oral and parenteral calcitriol for the management of end-stage renal disease. Contrib Nephrol 1991; 90: 166-182
57. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279
58. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721
59. Herrmann P, Ritz E, Schmidt-Gayk H et al. Comparison of intermittent and continuous oral administration of calcitriol. in dialysis patients: a randomized prospective trial. Nephron 1994; 67: 48-53
60. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000; 57: 282-292
61. Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432
62. Tan AU Jr, Levine BS, Mazess RB et al. Effective suppression of parathyroid hormone by 1 α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-323
63. Nemeth EF. Calcium receptors as novel drug targets. In: Bilezikian, JP, Raisz, LG, Rodan, GA, eds. Principles in Bone Biology. Academic Press, Inc., San Diego: 1996: 1019-1035
64. Goodman WG, Frazao JM, Goodkin DA et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-445
65. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant 2002; 17: 204-207
66. Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-1024
67. Wada M, Nagano N, Furuya Y et al. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57: 50-58
68. Amling M, Priemel M, Holzmann T et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999; 140: 4982-4987